BofA Keeps Straumann at Buy Ahead of Q2 Results; Forecasts Nudged Higher

BofA Global Research expects Straumann Holding (STMN.SW) to report better-than-expected organic sales in the second quarter when it releases its latest earnings report on Aug. 19. The Swiss dental products company's sales are anticipated to increase 8.3% organically in the quarter, 60 basis points ahead of consensus, according to BofA's earnings preview note published Thursday. "We expect a beat across all regions. EMEA doesn't face stocking comps anymore and we expect it to accelerate Q/Q. We see patient flow stable Q/Q in NAM with revenue growth likely similar to 1Q, driven by iEXCEL and SIRIOS launches," the research firm said. "Excellent and consistent execution, further share gains in implants and across new adjacent businesses, as well as opportunities for future earnings upgrades leave us positive on Straumann. Valuation is demanding (c27x FY27E P/E) but justified in our view as Straumann is a unique asset and remains today one of the only stock in the MedTech 'quality' bucket with ability to deliver consistent double-digit revenue and EPS growth over the mid-term." As such, analysts nudged up their 2026 and 2027 EPS estimates to 3.35 francs and 3.93 francs,.